Imidazoline I2 receptors: Target for new analgesics?

European Journal of Pharmacology

Volumn 658, Issue 2-3, 2011, Pages 49-56

  Li, Jun Xu ^a   Zhang, Yanan ^b  

^a UNIVERSITY AT BUFFALO   (United States)

^b RTI INTERNATIONAL   (United States)

Author keywords

Imidazoline I2 receptor; Opioid; Pain

Indexed keywords

2 (2 BENZOFURANYL)IMIDAZOLE; 2 (2 IMIDAZOLIN 2 YL)QUINOLINE; 2 BFI; AGANODINE; AGMATINE; ANALGESIC AGENT; DIPHENYZOLINE; IDAZOXAN; IMIDAZOLINE I2 RECEPTOR; IMIDAZOLINE RECEPTOR; MORPHINE; NARCOTIC ANALGESIC AGENT; PHENYZOLINE; RS 45041 190; TRACIZOLINE; UNCLASSIFIED DRUG; IMIDAZOLINE RECEPTOR 2; LIGAND;

ANALGESIA; ANALGESIC ACTIVITY; CANCER PAIN; CONSTIPATION; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; DRUG USE; HUMAN; HYPERALGESIA; INFLAMMATION; NEUROPATHIC PAIN; NONHUMAN; PAIN; POSTOPERATIVE PAIN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN TARGETING; PRURITUS; REVIEW; SINGLE DRUG DOSE; STRUCTURE ACTIVITY RELATION; ANIMAL; CHEMISTRY; METABOLISM;

ANALGESICS; ANIMALS; HUMANS; IMIDAZOLINE RECEPTORS; LIGANDS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 79953783763     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2011.02.038     Document Type: Review

References (90)

1. Aggarwal, S., Shavalian, B., Kim, E., Rawls, S.M., 2009. Agmatine enhances cannabinoid action in the hot-plate assay of thermal nociception. Pharmacol. Biochem. Behav. 93, 426-432.
2. Ahlgren, S.C., Levine, J.D., 1993. Mechanical hyperalgesia in streptozotocin-diabetic rats. Neuroscience 52, 1049-1055. (Pubitemid 23063547)
3. American Pain Foundation, 2010. http://www.painfoundation.org/newsroom/ reporterresources/pain-facts-figures.html. Retrieved on Dec. 5.
4. Aricioglu, F., Korcegez, E., Bozkurt, A., Ozyalcin, S., 2003. Effect of agmatine on acute and mononeuropathic pain. Ann. NY Acad. Sci. 1009, 106-115.
5. Aricioglu, F., Means, A., Regunathan, S., 2004. Effect of agmatine on the development of morphine dependence in rats: potential role of cAMP system. Eur. J. Pharmacol. 504, 191-197.
6. Aricioglu-Kartal, F., Uzbay, I.T., 1997. Inhibitory effect of agmatine on naloxone-precipitated abstinence syndrome in morphine dependent rats. Life Sci. 61, 1775-1781. (Pubitemid 27440632)
7. Armah, B.I., Hofferber, E., Stenzel, W., 1988. General pharmacology of the novel centrally acting antihypertensive agent moxonidine. Arzneimittelforschung 38, 1426-1434.
8. Berkels, R., Taubert, D., Grundemann, D., Schomig, E., 2004. Agmatine signaling: odds and threads. Cardiovasc. Drug Rev. 22, 7-16.
9. Bhalla, S., Rapolaviciute, V., Gulati, A., 2011. Determination of alpha(2)-adrenoceptor and imidazoline receptor involvement in augmentation of morphine and oxycodone analgesia by agmatine and BMS182874. Eur. J. Pharmacol. 651, 109-121.
10. 2-imidazoline ligands. Br. J. Pharmacol. 125, 175-185.
11. Bousquet, P., Bricca, G., Dontenwill, M., Feldman, J., Greney, H., Belcourt, A., Stutzmann, J., Tibirica, E., 1992. From the alpha 2-adrenoceptors to the imidazoline preferring receptors. Fundam. Clin. Pharmacol. 6 (Suppl 1), 15S-21S.
12. 2 imidazoline receptors. Br. J. Pharmacol. 116, 1737-1744.
13. Cherny, N.I., 2001. The pharmacological management of cancer pain. Eur. J. Cancer 37 (Suppl 7), S265-S278.
14. Courteix, C., Privat, A.M., Pelissier, T., Hernandez, A., Eschalier, A., Fialip, J., 2007. Agmatine induces antihyperalgesic effects in diabetic rats and a superadditive interaction with R(-)-3-(2-carboxypiperazine-4-yl)-propyl-1- phosphonic acid, a N-methyl-D-aspartate-receptor antagonist. J. Pharmacol. Exp. Ther. 322, 1237-1245.
15. Dardonville, C., Rozas, I., 2004. Imidazoline binding sites and their ligands: an overview of the different chemical structures. Med. Res. Rev. 24, 639-661.
16. Deandrea, S., Montanari, M., Moja, L., Apolone, G., 2008. Prevalence of undertreatment in cancer pain. A review of published literature. Ann. Oncol. 19, 1985-1991.
17. 2 receptors. Eur. J. Pharmacol. 333, 9-15.
18. Dogrul, A., Coskun, I., Uzbay, T., 2006. The contribution of alpha-1 and alpha-2 adrenoceptors in peripheral imidazoline and adrenoceptor agonist-induced nociception. Anesth. Analg. 103, 471-477.
19. Eglen, R.M., Hudson, A.L., Kendall, D.A., Nutt, D.J., Morgan, N.G., Wilson, V.G., Dillon, M.P., 1998. 'Seeing through a glass darkly': casting light on imidazoline 'I' sites. Trends Pharmacol. Sci. 19, 381-390.
20. Fairbanks, C.A., Wilcox, G.L., 1997. Acute tolerance to spinally administered morphine comparesmechanisticallywith chronically inducedmorphine tolerance. J. Pharmacol. Exp. Ther. 282, 1408-1417.
21. Fairbanks, C.A., Wilcox, G.L., 1999. Moxonidine, a selective alpha2-adrenergic and imidazoline receptor agonist, produces spinal antinociception in mice. J. Pharmacol. Exp. Ther. 290, 403-412.
22. Fairbanks, C.A., Nguyen, H.O., Grocholski, B.M., Wilcox, G.L., 2000a. Moxonidine, a selective imidazoline-alpha2-adrenergic receptor agonist, produces spinal synergistic antihyperalgesia with morphine in nerve-injured mice. Anesthesiology 93, 765-773.
23. Fairbanks, C.A., Posthumus, I.J., Kitto, K.F., Stone, L.S., Wilcox, G.L., 2000b. Moxonidine, a selective imidazoline/alpha(2) adrenergic receptor agonist, synergizes with morphine and deltorphin II to inhibit substance P-induced behavior in mice. Pain 84, 13-20.
24. Fairbanks, C.A., Schreiber, K.L., Brewer, K.L., Yu, C.G., Stone, L.S., Kitto, K.F., Nguyen, H.O., Grocholski, B.M., Shoeman, D.W., Kehl, L.J., Regunathan, S., Reis, D.J., Yezierski, R.P., Wilcox, G.L., 2000c. Agmatine reverses pain induced by inflammation, neuropathy, and spinal cord injury. Proc. Natl. Acad. Sci. U. S. A. 97, 10584-10589.
25. Fairbanks, C.A., Stone, L.S., Wilcox, G.L., 2009. Pharmacological profiles of alpha 2 adrenergic receptor agonists identified using genetically altered mice and isobolographic analysis. Pharmacol. Ther. 123, 224-238.
26. Farsang, C., Kapocsi, J., 1999. Imidazoline receptors: from discovery to antihypertensive therapy (facts and doubts). Brain Res. Bull. 49, 317-331. (Pubitemid 29368209)
27. Fenton, C., Keating, G.M., Lyseng-Williamson, K.A., 2006. Moxonidine: a review of its use in essential hypertension. Drugs 66, 477-496.
28. 2 receptor selective ligand BU224 in naive rats and rats exposed to the stress of the forced swim test. Psychopharmacology (Berl) 167, 195-202.
29. Gadotti, V.M., Tibola, D., Paszcuk, A.F., Rodrigues, A.L., Calixto, J.B., Santos, A.R., 2006. Contribution of spinal glutamatergic receptors to the antinociception caused by agmatine in mice. Brain Res. 1093, 116-122. (Pubitemid 43970714)
30. 2-IBS selectivity within a series of 2-phenoxymethylimidazoline analogues. J. Med. Chem. 46, 2169-2176.
31. 2-imidazoline binding sites in positive and negative morphine analgesia modulatory effects. Eur. J. Pharmacol. 553, 73-81.
32. 2-imidazoline binding sites nature and functions. J. Med. Chem. 51, 5130-5134.
33. Gutstein, H.B., Akil, H., 2001. Opioid analgesics, In: Hardman, J.G., Limbird, L.E., Gilman, A.G. (Eds.), Goodman & Gilman's The Pharmacological Basis of Therapeutics, 10 ed. McGraw-Hill, New York, pp. 569-619.
34. Halaris, A., Piletz, J.E., 2003. Relevance of imidazoline receptors and agmatine to psychiatry: a decade of progress. Ann. NY Acad. Sci. 1009, 1-20.
35. Halaris, A., Plietz, J., 2007. Agmatine: metabolic pathway and spectrum of activity in brain. CNS Drugs 21, 885-900. (Pubitemid 47557104)
36. Head, G.A., Mayorov, D.N., 2006. Imidazoline receptors, novel agents and therapeutic potential. Cardiovasc. Hematol. Agents Med. Chem. 4, 17-32.
37. Horvath, G., Kekesi, G., Dobos, I., Szikszay, M., Klimscha, W., Benedek, G., 1999. Effect of intrathecal agmatine on inflammation-induced thermal hyperalgesia in rats. Eur. J. Pharmacol. 368, 197-204.
38. Houghton, A.K., Westlund, K.N., 1996. An I2 imidazoline ligand, RS 45041, potentiates hyperalgesia in acute arthritis. NeuroReport 7, 1497-1501. (Pubitemid 26281130)
39. Jackson, H.C., Griffin, I.J., Nutt, D.J., 1991. The effects of idazoxan and other alpha 2-adrenoceptor antagonists on food and water intake in the rat. Br. J. Pharmacol. 104, 258-262.
40. 2 imidazoline ligand, in rats. Ann. NY Acad. Sci. 881, 369-371.
41. Karadag, H.C., Ulugol, A., Tamer, M., Ipci, Y., Dokmeci, I., 2003. Systemic agmatine attenuates tactile allodynia in two experimental neuropathic pain models in rats. Neurosci. Lett. 339, 88-90.
42. Kawecka-Jaszcz, K., Czarnecka, D., Klocek, M., Zabojszcz, M., Kucharska, M., Jaworski, R., Pachocki, R., 2006. Rilmenidine - its antihypertensive efficacy, safety and impact on quality of life in perimenopausal women with mild to moderate essential hypertension. Blood Press. 15, 51-58.
43. Kekesi, G., Dobos, I., Benedek, G., Horvath, G., 2004a. The antinociceptive potencies and interactions of endogenous ligands during continuous intrathecal administration: adenosine, agmatine, and endomorphin-1. Anesth. Analg. 98, 420-426.
44. Kekesi, G., Joo, G., Csullog, E., Peter-Szabo, M., Benedek, G., Horvath, G., 2004b. Dose-independent antinociceptive interaction of endogenous ligands at the spinal level. Brain Res. 1029, 93-102. (Pubitemid 39463311)
45. Kenakin, T., Onaran, O., 2002. The ligand paradox between affinity and efficacy: can you be there and not make a difference? Trends Pharmacol. Sci. 23, 275-280. (Pubitemid 34655733)
46. Keynan, O., Mirovsky, Y., Dekel, S., Gilad, V.H., Gilad, G.M., 2010. Safety and efficacy of dietary agmatine sulfate in lumbar disc-associated radiculopathy. An open-label, dose-escalating study followed by a randomized, double-blind, placebo-controlled trial. Pain Med. 11, 356-368.
47. Kim, S.H., Chung, J.M., 1992. An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat. Pain 50, 355-363.
48. Kissin, I., 2010. The development of new analgesics over the past 50 years: a lack of real breakthrough drugs. Anesth. Analg. 110, 780-789.
49. Kitto, K.F., Fairbanks, C.A., 2006. Supraspinally administered agmatine prevents the development of supraspinal morphine analgesic tolerance. Eur. J. Pharmacol. 536, 133-137.
50. Kolesnikov, Y., Jain, S., Pasternak, G.W., 1996. Modulation of opioid analgesia by agmatine. Eur. J. Pharmacol. 296, 17-22.
51. Laughlin, T.M., Vanderah, T.W., Lashbrook, J., Nichols, M.L., Ossipov, M., Porreca, F., Wilcox, G.L., 1997. Spinally administered dynorphin A produces long-lasting allodynia: involvement of NMDA but not opioid receptors. Pain 72, 253-260. (Pubitemid 27321924)
52. Le Bars, D., Gozariu, M., Cadden, S.W., 2001. Animal models of nociception. Pharmacol. Rev. 53, 597-652.
53. Li, G., Regunathan, S., Barrow, C.J., Eshraghi, J., Cooper, R., Reis, D.J., 1994. Agmatine: an endogenous clonidine-displacing substance in the brain. Science 263, 966-969. (Pubitemid 24094560)
54. Li, J., Li, X., Pei, G., Qin, B.Y., 1999a. Analgesic effect of agmatine and its enhancement on morphine analgesia in mice and rats. Zhongguo Yao Li Xue Bao 20, 81-85. (Pubitemid 29042469)
55. Li, J., Li, X., Pei, G., Qin, B.Y., 1999b. Effects of agmatine on tolerance to and substance dependence on morphine in mice. Zhongguo Yao Li Xue Bao 20, 232-238. (Pubitemid 29135321)
56. 2-site-specific ligands and monoamine oxidase inhibitors in rats with a unilateral 6-hydroxydopamine lesion of the nigrostriatal pathway. Br. J. Pharmacol. 143, 952-959.
57. Moore, R.A., McQuay, H.J., 2005. Prevalence of opioid adverse events in chronic nonmalignant pain: systematic review of randomised trials of oral opioids. Arthritis Res. Ther. 7, R1046-R1051.
58. Morgan, N.G., Chan, S.L., 2001. Imidazoline binding sites in the endocrine pancreas: can they fulfil their potential as targets for the development of new insulin secretagogues? Curr. Pharm. Des. 7, 1413-1431.
59. Onal, A., Soykan, N., 2001. Agmatine produces antinociception in tonic pain in mice. Pharmacol. Biochem. Behav. 69, 93-97.
60. Onal, A., Delen, Y., Ulker, S., Soykan, N., 2003. Agmatine attenuates neuropathic pain in rats: possible mediation of nitric oxide and noradrenergic activity in the brainstem and cerebellum. Life Sci. 73, 413-428. (Pubitemid 36577566)
61. Paszcuk, A.F., Gadotti, V.M., Tibola, D., Quintao, N.L., Rodrigues, A.L., Calixto, J.B., Santos, A.R., 2007. Anti-hypernociceptive properties of agmatine in persistent inflammatory and neuropathic models of pain in mice. Brain Res. 1159, 124-133. (Pubitemid 47071767)
62. Pigini, M., Bousquet, P., Carotti, A., Dontenwill, M., Giannella, M., Moriconi, R., Piergentili, A., Quaglia, W., Tayebati, S.K., Brasili, L., 1997. Imidazoline receptors: qualitative structure-activity relationships and discovery of tracizoline and benazoline. Two ligands with high affinity and unprecedented selectivity. Bioorg. Med. Chem. 5, 833-841.
63. Piletz, J.E., Ivanov, T.R., Sharp, J.D., Ernsberger, P., Chang, C.H., Pickard, R.T.,Gold, G., Roth, B., Zhu, H., Jones, J.C., Baldwin, J., Reis, D.J., 2000. Imidazoline receptor antisera-selected (IRAS) cDNA: cloning and characterization. DNA Cell Biol. 19, 319-329. (Pubitemid 30419134)
64. Piletz, J.E., Wang, G., Zhu, H., 2003. Cell signaling by imidazoline-1 receptor candidate, IRAS, and the nischarin homologue. Ann. NY Acad. Sci. 1009, 392-399.
65. Polidori, C., Gentili, F., Pigini, M., Quaglia, W., Panocka, I., Massi, M., 2000. Hyperphagic effect of novel compounds with high affinity for imidazoline I(2) binding sites. Eur. J. Pharmacol. 392, 41-49.
66. Regunathan, S., 2006. Agmatine: biological role and therapeutic potentials in morphine analgesia and dependence. AAPS J. 8, E479-E484. (Pubitemid 44159202)
67. Regunathan, S., Reis, D.J., 1996. Imidazoline receptors and their endogenous ligands. Annu. Rev. Pharmacol. Toxicol. 36, 511-544.
68. Reis, D.J., Regunathan, S., 1998a. Agmatine: a novel neurotransmitter? Adv. Pharmacol. 42, 645-649.
69. Reis, D.J., Regunathan, S., 1998b. Agmatine: an endogenous ligand at imidazoline receptors may be a novel neurotransmitter in brain. J. Auton. Nerv. Syst. 72, 80-85.
70. Reis, D.J., Regunathan, S., 1999. Agmatine: an endogenous ligand at imidazoline receptors is a novel neurotransmitter. Ann. NY Acad. Sci. 881, 65-80.
71. Reis, D.J., Regunathan, S., 2000. Is agmatine a novel neurotransmitter in brain? Trends Pharmacol. Sci. 21, 187-193. (Pubitemid 30243201)
72. Roberts, J.C., Grocholski, B.M., Kitto, K.F., Fairbanks, C.A., 2005. Pharmacodynamic and pharmacokinetic studies of agmatine after spinal administration in the mouse. J. Pharmacol. Exp. Ther. 314, 1226-1233.
73. Roerig, S.C., 2003. Spinal and supraspinal agmatine activate different receptors to enhance spinal morphine antinociception. Ann. NY Acad. Sci. 1009, 116-126.
74. Ruan, X., 2007. Drug-related side effects of long-term intrathecal morphine therapy. Pain Physician 10, 357-366.
75. 2/adrenergic alpha2 receptor ligands. Bioorg. Med. Chem. 14, 6679-6685.
76. Sanchez-Blazquez, P., Boronat, M.A., Olmos, G., Garcia-Sevilla, J.A., Garzon, J., 2000. Activation of I(2)-imidazoline receptors enhances supraspinal morphine analgesia in mice: a model to detect agonist and antagonist activities at these receptors. Br. J. Pharmacol. 130, 146-152.
77. Santos, A.R., Gadotti, V.M., Oliveira, G.L., Tibola, D., Paszcuk, A.F., Neto, A., Spindola, H.M., Souza, M.M., Rodrigues, A.L., Calixto, J.B., 2005. Mechanisms involved in the antinociception caused by agmatine in mice. Neuropharmacology 48, 1021-1034. (Pubitemid 40602610)
78. Shannon, H.E., Lutz, E.A., 2000. Effects of the I(1) imidazoline/alpha(2) -adrenergic receptor agonist moxonidine in comparison with clonidine in the formalin test in rats. Pain 85, 161-167.
79. Sica, D.A., 2007. Centrally acting antihypertensive agents: an update. J. Clin. Hypertens. (Greenwich) 9, 399-405.
80. Stalnikowicz, R., Mahamid, R., Kaspi, S., Brezis, M., 2005. Undertreatment of acute pain in the emergency department: a challenge. Int. J. Qual. Health Care 17, 173-176.
81. Stewart, W.F., Ricci, J.A., Chee, E., Morganstein, D., Lipton, R., 2003. Lost productive time and cost due to common pain conditions in the US workforce. JAMA 290, 2443-2454. (Pubitemid 37430544)
82. Su, R.B., Li, J., Gao, K., Pei, G., Qin, B.Y., 2000. Influence of idazoxan on analgesia, tolerance, and physical dependence of morphine in mice and rats in vivo. Acta Pharmacol. Sin. 21, 1011-1015.
83. Su, R.B., Lu, X.Q., Huang, Y., Liu, Y., Gong, Z.H., Wei, X.L., Wu, N., Li, J., 2008. Effects of intragastric agmatine on morphine-induced physiological dependence in beagle dogs and rhesus monkeys. Eur. J. Pharmacol. 587, 155-162.
84. Thomas, J.R., Cooney, G.A., Slatkin, N.E., 2008. Palliative care and pain: new strategies for managing opioid bowel dysfunction. J. Palliat.Med. 11 (Suppl 1), S1-S19 quiz S21-12.
85. Urban, J.D., Clarke, W.P., von Zastrow, M., Nichols, D.E., Kobilka, B., Weinstein, H., Javitch, J.A., Roth, B.L., Christopoulos, A., Sexton, P.M., Miller, K.J., Spedding, M., Mailman, R.B., 2007. Functional selectivity and classical concepts of quantitative pharmacology. J. Pharmacol. Exp. Ther. 320, 1-13.
86. Wu, N., Su, R.B., Li, J., 2008. Agmatine and imidazoline receptors: their role in opioid analgesia, tolerance and dependence. Cell. Mol. Neurobiol. 28, 629-641.
87. Wuarin-Bierman, L., Zahnd, G.R., Kaufmann, F., Burcklen, L., Adler, J., 1987. Hyperalgesia in spontaneous and experimental animal models of diabetic neuropathy. Diabetologia 30, 653-658.
88. Yeomans, D.C., Proudfit, H.K., 1994. Characterization of the foot withdrawal response to noxious radiant heat in the rat. Pain 59, 85-94. (Pubitemid 24311173)
89. Yeomans, D.C., Pirec, V., Proudfit, H.K., 1996. Nociceptive responses to high and low rates of noxious cutaneous heating are mediated by different nociceptors in the rat: behavioral evidence. Pain 68, 133-140. (Pubitemid 126407765)
90. Yesilyurt, O., Uzbay, I.T., 2001. Agmatine potentiates the analgesic effect of morphine by an alpha(2)-adrenoceptor-mediated mechanism in mice. Neuropsychopharmacology 25, 98-103. (Pubitemid 32493826)